Cargando…
Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy
BACKGROUND: Addition of oxaliplatin to capecitabine remains controversial for locally advanced rectal cancer (LARC). And cumulative oxaliplatin dose (COD) varied among clinical trials showing different therapeutic effects of this regimen. The objective of this study was to explore how COD affected t...
Autores principales: | Chang, Hui, Tao, Ya-lan, Jiang, Wu, Chen, Chen, Liu, Shi-liang, Ye, Wei-jun, Gao, Yuan-hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268650/ https://www.ncbi.nlm.nih.gov/pubmed/32487091 http://dx.doi.org/10.1186/s12885-020-06988-x |
Ejemplares similares
-
Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer
por: Fu, Xing-Li, et al.
Publicado: (2017) -
Rectal cancer patients with downstaging after neoadjuvant chemoradiotherapy and radical resection do not benefit from adjuvant chemotherapy
por: Zhang, Hang, et al.
Publicado: (2020) -
Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis: Oxaliplatin in neoadjuvant treatment for rectal cancer
por: De Felice, Francesca, et al.
Publicado: (2017) -
Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy
por: Huang, Xuan-zhang, et al.
Publicado: (2016) -
Adjuvant therapy in patients with rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and radical resection in pathological stages I–III
por: Lino-Silva, Leonardo S., et al.
Publicado: (2020)